Literature DB >> 9823562

[Chronic interstitial nephritis and mesalazine: 3 new cases?].

M Brouillard1, J D Gheerbrant, Y Gheysens, D Fleury, M Devred, M Hazzan, J F Colombel.   

Abstract

We report three new cases of chronic interstitial nephritis occurring in two patients with Crohn's disease and one patient with ulcerative colitis treated with mesalazine. In the three cases asymptomatic renal disease was revealed by an increase in serum creatinine which was normal before treatment. Renal biopsy showed features of severe chronic interstitial nephritis. Mesalazine withdrawal and administration of steroids in two cases led to partial improvement of renal function. Mechanism of renal toxicity of mesalazine is unknown. These observations stress the need for monitoring renal function in patients with inflammatory bowel disease treated with mesalazine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9823562

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  6 in total

1.  Current medical therapy of inflammatory bowel disease.

Authors:  Kiron M Das; Sherif A Farag
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

2.  Role of tumor necrosis factor inhibitor in granulomatous interstitial nephritis secondary to Crohn's disease.

Authors:  Manish K Saha; Hamieh Tarek; Vishal Sagar; Paul Abraham
Journal:  Int Urol Nephrol       Date:  2012-12-30       Impact factor: 2.370

Review 3.  Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

4.  Medical treatment of ulcerative colitis.

Authors:  Uma Mahadevan
Journal:  Clin Colon Rectal Surg       Date:  2004-02

5.  Renal effects of long-term treatment with 5-aminosalicylic acid.

Authors:  H Patel; A Barr; K N Jeejeebhoy
Journal:  Can J Gastroenterol       Date:  2009-03       Impact factor: 3.522

Review 6.  Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.

Authors:  A Prakash; A Markham
Journal:  Drugs       Date:  1999-03       Impact factor: 11.431

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.